Mercy BioAnalytics Joins Groundbreaking NHS Multicancer Blood Test Trial

Mercy BioAnalytics Joins Pioneering NHS Multicancer Blood Test Trial

Mercy BioAnalytics, Inc., a leading company focused on blood-based tests for early cancer detection, has recently been chosen to participate in a pivotal clinical trial known as STRIDE-RCT. This trial, funded by the UK's Office for Life Sciences and spearheaded by the University of Birmingham, aims to evaluate the effectiveness of blood tests in helping general practitioners identify patients who require urgent investigations for possible cancer.

The STRIDE-RCT initiative is one of the first of its kind in the UK, involving over 20,000 National Health Service (NHS) patients across at least 200 general practices in England. The study is particularly addressing the challenges clinicians face when patients present with non-specific abdominal symptoms, which can often indicate serious underlying conditions like cancer.

Trial Aims and Patient Involvement

As part of the trial, adults aged 45 and older who visit participating GP practices with symptoms such as persistent bloating, discomfort, or other vague abdominal issues will have the opportunity to participate. This is particularly crucial as current statistics reveal that approximately 71,000 individuals in the UK are diagnosed annually with cancers such as pancreatic, stomach, liver, ovarian, or bowel cancer, resulting in nearly 35,000 deaths each year.

Secretary of State for Health and Social Care, Yvette Cooper, emphasized the significance of early cancer detection. She stated, "The earlier cancers are diagnosed, the more chance they can be successfully treated, and lives can be saved." This sentiment encapsulates the urgency of the trial, which aims to determine whether simple blood tests can significantly enhance the ability of GPs to diagnose and manage potential cancer cases more effectively.

Patients participating in the trial will provide a blood sample during routine check-ups at their GP practices. These samples will be analyzed in conjunction with routine blood work to see if they can aid GPs in making quicker, more informed decisions regarding urgent referrals to specialized care.

Mercy BioAnalytics' Role and Innovation

Mercy's contribution to this groundbreaking trial is underpinned by its innovative liquid biopsy platform, which powers the company's Evident™-branded tests. This platform is designed to detect various types of cancer through the analysis of blood samples, extracting vital information from extracellular vesicles and particles that carry unique signatures indicative of cancer.

Dawn Mattoon, Ph.D., CEO of Mercy BioAnalytics, expressed pride in the company's involvement, stating, "We are delighted to contribute our testing platform to this important multicancer trial. STRIDE-RCT provides an opportunity to assess how innovative blood testing can help clinicians identify patients who need rapid workup to enable earlier cancer detection while optimizing the use of precious healthcare resources."

The ultimate goal of STRIDE-RCT is to develop a model where rapid testing can facilitate earlier diagnosis and treatment of various cancers, potentially revolutionizing how these conditions are approached within the healthcare system. The study is integral to a larger National Cancer Plan that seeks to improve cancer outcomes through innovation.

Conclusion

Mercy BioAnalytics' selection for the STRIDE-RCT trial marks a significant step forward in the quest for early cancer detection methods. As the trial progresses, it promises to offer invaluable insights into the intersection of advanced technology and healthcare, potentially leading to lifesaving advancements in cancer diagnosis and patient management. With the prospect of bettering the lives of many, this trial stands as a beacon of hope in the fight against cancer.